Abstract
Comparable to the anti-craving compound acamprosate, caroverine reduces alcohol withdrawal symptoms by an antagonism at ionotropic glutamate receptors and a blockade of calcium channels. The present study examines the effect of caroverine in a craving model, in which acamprosate has proved effective before. A place aversion was induced by a conditioned morphine withdrawal by administration of the opioid antagonist naloxone (0.1 mg/kg, s.c.) 5–6 days after the subcutaneous implantation of a morphine pellet in rats. Testing in the drug-free state, the acquisition of a conditioned aversion against the naloxone-associated cues was inhibited by pretreatment with caroverine (5 mg/kg, i.p.). This result corroborates the involvement of excitatory glutamate and calcium in the development of conditioned withdrawal and craving. It offers further evidence for the hypothesis that these neuronal systems are altered during withdrawal in a similar way by ethanol and opiates.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
